Table 1.
MfERG data at baseline and during follow-up
| Baseline | ANOVA vs AMD-P | 6 months | ANOVA vs baseline | |||||
|---|---|---|---|---|---|---|---|---|
| Mean | SD | f (1,27) | p | Mean | SD | f (1,27) | p | |
| R1 RAD (nV/degree2) | ||||||||
| AMD-P (n = 14) | 65.24 | 14.06 | 65.12 | 20.19 | 0.001 | 0.991 | ||
| AMD-M (n = 14) | 61.52 | 15.22 | 0.43 | 0.516 | 85.02 | 27.91 | 7.64 | 0.010 |
| R2 RAD (nV/degree2) | ||||||||
| AMD-P (n = 14) | 26.93 | 5.43 | 28.08 | 8.21 | 0.17 | 0.685 | ||
| AMD-M (n = 14) | 26.65 | 7.47 | 0.02 | 0.886 | 34.78 | 12.46 | 4.48 | 0.044 |
| R3 RAD (nV/degree2) | ||||||||
| AMD-P (n = 14) | 16.07 | 3.94 | 18.58 | 4.25 | 2.91 | 0.099 | ||
| AMD-M (n = 14) | 15.24 | 4.55 | 0.21 | 0.651 | 18.39 | 4.98 | 3.07 | 0.092 |
| R4 RAD (nV/degree2) | ||||||||
| AMD-P (n = 14) | 11.42 | 3.61 | 12.98 | 3.61 | 1.34 | 0.258 | ||
| AMD-M (n = 14) | 11.91 | 2.73 | 0.17 | 0.691 | 12.81 | 3.24 | 0.63 | 0.434 |
| R5 RAD (nV/degree2) | ||||||||
| AMD-P (n = 14) | 8.24 | 3.06 | 8.42 | 2.37 | 0.03 | 0.864 | ||
| AMD-M (n = 14) | 7.91 | 3.21 | 0.42 | 0.524 | 8.81 | 2.10 | 0.77 | 0.388 |
Mean ± standard deviation (SD) of multifocal electroretinogram (mfERG) R1–R5 N1–P1 response amplitude density (RAD) values detected at baseline and after 6 months of follow-up in AMD eyes treated with placebo (AMD-P eyes) or with Macuprev® (AMD-M eyes). R1–R5 refers to localized mfERG responses averaged in five eccentricity areas between the fovea and mid-periphery: 0–2.5° (R1), 2.5–5° (R2), 5–10° (R3), 10–15° (R4), and 15–20° (R5). Statistics: analysis of variance (ANOVA) between AMD-P and AMD-M groups at baseline and between AMD-P and AMD-M groups at 6 months vs baseline; n number of eyes